Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection (Lurbinectedin) in Patients With Metastatic Small Cell Lung Cancer (SCLC) in Real-World Practice
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Patients who voluntarily provide written consent for personal information collection and utilization after receiving an explanation about the objective and methods of the study
• Patients who have received or are scheduled to receive Zepzelca™ inj., according to domestic approval indications
• Patients with metastatic SCLC who have failed first-line platinum-based chemotherapy
Locations
Other Locations
Republic of Korea
Seoul National University Boramae Medical Center
RECRUITING
Seoul
Contact Information
Primary
Shinyoung Oh
syoh@boryung.co.kr
+82-2-708-8000
Time Frame
Start Date: 2023-08-16
Estimated Completion Date: 2025-09
Participants
Target number of participants: 300
Related Therapeutic Areas
Sponsors
Leads: Boryung Pharmaceutical Co., Ltd